ToxSci Advance Access published online on June 19, 2006
Toxicological Sciences, doi:10.1093/toxsci/kfl042
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Institute of Occupational, Social, and Environmental Medicine, University of Erlangen, D-91054 Erlangen, Germany
* To whom correspondence should be addressed. Biomonitoring programs in the United States and Europe demonstrate the vast array of data that are publicly available for the evaluation of exposure trends, identification of susceptible populations, detection of emerging chemical risks, the conduct of epidemiology studies, and evaluation of risk reduction strategies. To cultivate international discussion on these issues, the ILSI Health and Environmental Sciences Institute convened a scientific session at its Annual Meeting in January 2006 on "Integration of Biomonitoring Exposure Data into the Risk Assessment Process." This Forum paper presents perspectives from session speakers on the biomonitoring activities of the Centers for Disease Control and Prevention, the US Environmental Protection Agency, the National Research Council Committee on Human Biomonitoring for Environmental Toxicants, the German Commission on Human Biomonitoring, and the HESI Biomonitoring Technical Committee. Speakers noted that better estimates of biological concentrations of substances in the tissues of human populations can be combined with other exposure indices, as well as epidemiological and toxicology data, to improve risk estimates. With this type of combined data, the potential also exists to define exposure levels at which hazard and risk are of minimal concern. Limitations in interpreting biomonitoring data were discussed, including the need for different criteria for applying biomonitoring data for exposure assessment, risk assessment, risk management, or disease prevention purposes. As efforts and resources are expended to improve the ability to apply biomonitoring exposure data in the risk assessment process, it is equally important to communicate the significance of such data to the public.
Received April 14, 2006
Accepted June 9, 2006
Forum
Meeting Report: Strategic Biomonitoring Initiatives: Moving the Science Forward
Jürgen Angerer 1,
Michael G. Bird 2,
Thomas A. Burke 3,
Nancy G. Doerrer 4 *,
Larry Needham 5,
Steven H. Robison 6,
Linda Sheldon 7,
and
Hal Zenick 8
2 ExxonMobil Biomedical Sciences, Inc., Annandale, New Jersey, USA 08801
3 Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA 21205
4 ILSI Health and Environmental Sciences Institute, Washington, DC, USA 20005
5 Centers for Disease Control and Prevention, Atlanta, Georgia, USA 30341
6 The Procter & Gamble Company, Cincinnati, Ohio, USA 45253
7 US Environmental Protection Agency, National Exposure Research Laboratory, Research Triangle Park, North Carolina, USA 27711
8 US Environmental Protection Agency, National Health and Environmental Effects Research Laboratory, Research Triangle Park, North Carolina, USA 27711
Nancy G. Doerrer, E-mail: ndoerrer{at}hesiglobal.org
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
H. M. Koch and A. M. Calafat Human body burdens of chemicals used in plastic manufacture Phil Trans R Soc B, July 27, 2009; 364(1526): 2063 - 2078. [Abstract] [Full Text] [PDF] |
||||
